NEW YORK, NY / ACCESSWIRE / February 2, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
GPS Shareholders Click Here: https://www.zlk.com/pslra-1/the-gap-inc-lawsuit-submission-form?prid=36179&wire=1
FXLV Shareholders Click Here: https://www.zlk.com/pslra-1/f45-training-lawsuit-submission-form?prid=36179&wire=1
FATE Shareholders Click Here: https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=36179&wire=1
* ADDITIONAL INFORMATION BELOW *
The Gap, Inc. (NYSE:GPS)
GPS Lawsuit on behalf of: investors who purchased November 24, 2021 - July 11, 2022
Lead Plaintiff Deadline : February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-gap-inc-lawsuit-submission-form?prid=36179&wire=1
According to the filed complaint, during the class period, The Gap, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were execution missteps in size and assortment at Old Navy related to BODEQUALITY, the Company's size-inclusivity campaign, which were adversely impacting Old Navy's margins and financial results; (2) contrary to the Company's statements, there were inventory risks relating to BODEQUALITY that were adversely affecting the Company's operations; and as a result (3) the Company's statements during the class period about the historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company, and were materially false and misleading and lacked a factual basis.
F45 Training Holdings Inc. (NYSE:FXLV)
This lawsuit is on behalf of all persons and entities that purchased or otherwise acquired the common stock of F45 pursuant and/or traceable to documents issued in connection with the Company's July 16, 2021 initial public offering.
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/f45-training-lawsuit-submission-form?prid=36179&wire=1
According to the filed complaint, 1) F45 Training could not maintain new franchise growth because it was offering more favorable payment terms to multi-unit franchisees; 2) F45 Training's lackluster pace of growth was also accompanied by a massive and unsustainable increase in F45 Training's accounts receivable and a similar, and equally unsustainable, decrease in its cash and cash equivalents; and 3) these practices were not sustainable at the time of the initial public offering, and when F45 Training could no longer sustain this defective business model, its growth rate and revenue plummeted.
Fate Therapeutics, Inc. (NASDAQ:FATE)
FATE Lawsuit on behalf of: investors who purchased April 2, 2020 - January 5, 2023
Lead Plaintiff Deadline : March 22, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=36179&wire=1
According to the filed complaint, during the class period, Fate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the global collaboration and option agreement for cell-based cancer immunotherapies that the Company entered into with Janssen Biotech, Inc. (the "Janssen Collaboration Agreement") was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement's on Fate's long-term clinical and commercial profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP